Skip to main content
. 2017 Nov 22;2017(11):CD012216. doi: 10.1002/14651858.CD012216.pub2

NCT02330510.

Trial name or title Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease (MITNEC C6)
Target condition and reference standard(s) Cognitive decline over two years of follow‐up, reference standard not specified
Index and comparator tests 18F‐florbetapir
Starting date 2014
Contact information Maryam Niapour, maryam.niapour@sunnybrook.ca
 Christopher JM Scott, christopher.scott@sri.utoronto.ca
Notes